Icagen, Inc announced a one year extension to a prior worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders.

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News